Pharmaceutical companies

The Aegate Ecosystem Partner Program is an innovative program aimed at enabling companies that develop and operate pharmacy dispensing software services to become compliant with the requirements of the new European Falsified Medicines Directive. In addition to compliance with the legislation the Aegate Safe Medicine Ecosystem Partner Program allows participants to benefit from a revenue share agreement with Aegate for integration of the Aegate service into the pharmacy dispensing software. The Partner Program also broadens the end-to-end services from specialised solution companies operating inside the manufacturing and distribution facilities.

Aegate is the global leading medicines authentication and verification company, which has been selected by the European Stakeholders as a solution service provider for the 28 European Union countries and the 5 European Economic Area Countries.The Aegate authentication solution enables pharmacy software providers to become compliant with the Falsified Medicine Directive and meet the detailed obligations contained within the Delegated Acts. The legislation requires pharmacists to perform a check to verify the authenticity of each pack of prescription medicines before being dispensed to a patient. This check may also be required to be performed on some over the counter medicines (OTC) deemed to be at risk of falsification. In addition the Falsified Medicines Directive also requires wholesalers to perform verification checks on some medicines, the Aegate solution also supports this check.


There are a very large number of pharmacy dispensing software systems and service providers across Europe. This reflects the variety of different pharmacy workflows in each country and the localisation typical in each specific market. The Aegate SAFE MEDICINE authentication service works through a non-invasive integration of a small agent into the dispensing software allowing the verification and authentication of a serialised pack against information held in a national repository system. The repository is populated with randomised serial codes supplied by the pharmaceutical manufacturer, these are either placed into the National repository directly by the pharmaceutical company or supplied from acentral European Hub.
The Aegate authentication service works by leveraging the architecture of each dispensing software to compare data that is generated each time a unique barcode is scanned on the medicine pack. The scan data containing the unique code is sent by the service to be authenticated at the Aegate national repository. The repository then determines whether or not there are any specific messages that need to be sent back to the Pharmacist to stop the dispensing of the medicine.These messages could be because the product is either Recalled, Expired, Suspect or the Authentication of that same code has already occurred at another dispensing point.
The Aegate authentication service works very quickly with each transaction taking a total of a quarter of a second for the complete round trip. The Aegate service has already verified 3 billion tags and is currently verifying 3 million tags a day. The pharmacist continues to operate as before as the service is designed to fit into the existing pharmacy workflow. However, the pharmacist is now compliant with the legislation. Importantly the Aegate service will only interrupt the dispensing process if an action is required, the message is displayed as “pop-up” on the pharmacists dispensing screen and this message must be acknowledged before the pharmacist can continue. This ensures that only authenticated medicines are given to the patient.
The branded partner program highlights the quality standards it brings together with the multiple national Patient Medication Record companies in the service of pharmacies and patients for medicine verification.

Aegate has already performed 41 integrations in Europe, through this activity Aegate has obtained experience that allows a fast and seamless integration to be completed. The integration is completed in a minimal time span and with a maximum support given to the software developers.

Revenues share from both the authentication service but also from other messaging services are an important value.
Aegate participates directly in revenues from both the entire European Medicine Verification Organisation. As well as this Aegate generates revenues driven by other messaging services directly related to specific medicine programs, such as messages for patient adherence to therapy, for reminders of vaccination, even specific messages including videos about how to take a medicine which can also be shared with patients.


Because the communication service is two-way it also allows an unlimited number of different ways to leverage the pharmacist in his or her role of pharmaceutical care provider.The Aegate service also opens new opportunities such as involving pharmacists in pharmaceutical research and clinical research, allowing both the pharmacist and the dispensing software company an incremental revenue stream.

Aegate works across all European Countries bringing together a community of 150 software service companies serving 170,000 pharmacies across the continent.
The Aegate European Digital Network which links all the pharmacies dispensing products to both the Pharmaceutical industry and its supply chain as well as the National Health Service and regulatory Bodies has a profound value to improving health care for patients and also improving the efficiency and effectiveness of the value chain.

1) Joint marketing participation and exposure at the European level
2) Revenue share linked to, messaging and patient services at the European and National levels.
3) Compliance to the Falsified Medicines Directive
4) Update and information on how the industry is moving across the EU
5) A voice and leverage vis a vis large pharmaceutical companies and associations
6) Better insight into the Falsified Medicine Directive at a national and European level

The Aegate Ecosystem Partner Program is an innovative program aimed at enabling companies that develop and operate pharmacy dispensing software services to become compliant with the requirements of the new European Falsified Medicines Directive. In addition to compliance with the legislation the Aegate Safe Medicine Ecosystem Partner Program allows participants to benefit from a revenue share agreement with Aegate for integration of the Aegate service into the pharmacy dispensing software. The Partner Program also broadens the end-to-end services from specialised solution companies operating inside the manufacturing and distribution facilities.

Aegate is the global leading medicines authentication and verification company, which has been selected by the European Stakeholders as a solution service provider for the 28 European Union countries and the 5 European Economic Area Countries.

The Aegate authentication solution enables pharmacy software providers to become compliant with the Falsified Medicine Directive and meet the detailed obligations contained within the Delegated Acts. The legislation requires pharmacists to perform a check to verify the authenticity of each pack of prescription medicines before being dispensed to a patient. This check may also be required to be performed on some over the counter medicines (OTC) deemed to be at risk of falsification. In addition the Falsified Medicines Directive also requires wholesalers to perform verification checks on some medicines, the Aegate solution also supports this check.

There are a very large number of pharmacy dispensing software systems and service providers across Europe. This reflects the variety of different pharmacy workflows in each country and the localisation typical in each specific market. The Aegate SAFE MEDICINE authentication service works through a non-invasive integration of a small agent into the dispensing software allowing the verification and authentication of a serialised pack against information held in a national repository system. The repository is populated with randomised serial codes supplied by the pharmaceutical manufacturer, these are either placed into the National repository directly by the pharmaceutical company or supplied from acentral European Hub.

The Aegate authentication service works by leveraging the architecture of each dispensing software to compare data that is generated each time a unique barcode is scanned on the medicine pack. The scan data containing the unique code is sent by the service to be authenticated at the Aegate national repository. The repository then determines whether or not there are any specific messages that need to be sent back to the Pharmacist to stop the dispensing of the medicine.These messages could be because the product is either Recalled, Expired, Suspect or the Authentication of that same code has already occurred at another dispensing point.

The Aegate authentication service works very quickly with each transaction taking a total of a quarter of a second for the complete round trip. The Aegate service has already verified 3 billion tags and is currently verifying 3 million tags a day. The pharmacist continues to operate as before as the service is designed to fit into the existing pharmacy workflow. However, the pharmacist is now compliant with the legislation. Importantly the Aegate service will only interrupt the dispensing process if an action is required, the message is displayed as “pop-up” on the pharmacists dispensing screen and this message must be acknowledged before the pharmacist can continue. This ensures that only authenticated medicines are given to the patient.

The branded partner program highlights the quality standards it brings together with the multiple national Patient Medication Record companies in the service of pharmacies and patients for medicine verification.


Aegate has already performed 41 integrations in Europe, through this activity Aegate has obtained experience that allows a fast and seamless integration to be completed. The integration is completed in a minimal time span and with a maximum support given to the software developers.

The benefits are substantial.

Revenues share from both the authentication service but also from other messaging services are an important value.

Aegate participates directly in revenues from both the entire European Medicine Verification Organisation. As well as this Aegate generates revenues driven by other messaging services directly related to specific medicine programs, such as messages for patient adherence to therapy, for reminders of vaccination, even specific messages including videos about how to take a medicine which can also be shared with patients.

Because the communication service is two-way it also allows an unlimited number of different ways to leverage the pharmacist in his or her role of pharmaceutical care provider.The Aegate service also opens new opportunities such as involving pharmacists in pharmaceutical research and clinical research, allowing both the pharmacist and the dispensing software company an incremental revenue stream.

Aegate works across all European Countries bringing together a community of 150 software service companies serving 170,000 pharmacies across the continent.

The Aegate European Digital Network which links all the pharmacies dispensing products to both the Pharmaceutical industry and its supply chain as well as the National Health Service and regulatory Bodies has a profound value to improving health care for patients and also improving the efficiency and effectiveness of the value chain.

1) Joint marketing participation and exposure at the European level

2) Revenue share linked to, messaging and patient services at the European and National levels.

3) Compliance to the Falsified Medicines Directive

4) Update and information on how the industry is moving across the EU

5) A voice and leverage vis a vis large pharmaceutical companies and associations

6) Better insight into the Falsified Medicine Directive at a national and European level